Orexin A (human, rat, mouse) (TFA)

Research use only, not for human use.

Endogenous agonist at orexin receptors (Ki values are 20 and 38 nM for OX1 and OX2 receptors respectively). Stimulates feeding following central administration and may be involved in the control of sleep-wake cycle and other hypothalamic functions.

Endogenous agonist at orexin receptors (Ki values are 20 and 38 nM for OX1 and OX2 receptors respectively). Stimulates feeding following central administration and may be involved in the control of sleep-wake cycle and other hypothalamic functions. (In Vitro):Orexin A human, rat, mouse TFA has high affinity for OX1R, with 38 nM IC50 and 34 nM EC50 values in the the [Ca2﹢]i transient assay.(In Vivo):Orexin A human, rat, mouse TFA (3-30 mg/kg; i.v.; 5 min pre-test) significantly increases the latency to response at 10 and 30 mg/kg i.v. when given 5 min pre-test from 24.8±2.0 s in vehicle-treated mice to 35.0±3.7 s and 45.7±4.5 s, respectively. Orexin A human, rat, mouse TFA (3, 10 and 30 mg/kg; i.v.) is given immediately before phenylp-quinone (PPQ) and increases the latency to the first PPQ-induced constriction from 357.4±35.2 s in vehicle-treated mice to 500.3±31.2 s at 10 mg/kg and 594.5±5.5 s at 30 mg/kg.

——

——

——

Others

Other Targets

——

——

——

——

3675.12

C154H244N47F3O46S4

>98% (HPLC)

——

——

Sequence:{Glp}-Pro-Leu-Pro-Asp-Cys-Cys-Arg-Gln-Lys-Thr-Cys-Ser-Cys-Arg-Leu-Tyr-Glu-Leu-Leu-His-Gly-Ala-Gly-Asn-His-Ala-Ala-Gly-IIE-Leu-Thr-Leu-NH2 (Disulfide bridge: Cys6-Cys12, Cys7-Cys14)

(-20℃)

With Ice Pack

≥ 2 years